Process for the preparation of safinamide mesylate intermediate
11111208 · 2021-09-07
Assignee
Inventors
- Ravishanker Kovi (Monroe Township, NJ, US)
- Jayaraman Kannappan (Vadodara, IN)
- Rajesh A Patel (Vadodara, IN)
- Daxeshkumar Prakashbhai Patel (Vadodara, IN)
Cpc classification
C07C303/22
CHEMISTRY; METALLURGY
C07C231/12
CHEMISTRY; METALLURGY
C07C237/06
CHEMISTRY; METALLURGY
C07C303/22
CHEMISTRY; METALLURGY
C07C45/64
CHEMISTRY; METALLURGY
C07C237/08
CHEMISTRY; METALLURGY
C07C237/08
CHEMISTRY; METALLURGY
C07C45/63
CHEMISTRY; METALLURGY
C07C45/64
CHEMISTRY; METALLURGY
C07C237/06
CHEMISTRY; METALLURGY
C07C47/575
CHEMISTRY; METALLURGY
C07C47/575
CHEMISTRY; METALLURGY
C07C231/12
CHEMISTRY; METALLURGY
International classification
C07C231/12
CHEMISTRY; METALLURGY
C07C237/06
CHEMISTRY; METALLURGY
C07C47/575
CHEMISTRY; METALLURGY
Abstract
The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.
Claims
1. A method for the preparation of a compound, comprising: a condensation reaction of 4-hydroxybenzaldehyde of formula II with 1-(chloromethyl)-3-fluorobenzene of formula III, using potassium carbonate, and potassium iodide in a solvent, and removing the solvent after completion of the condensation reaction, therewith producing crude 4-((3-fluorobenzyl)oxy)benzaldehyde of formula IV; treating the crude with n-heptane to remove genotoxic impurities; dissolving the treated crude in dichloromethane and treating the solution with potassium carbonate; and treating the treated solution with n-heptane to afford 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V having a purity greater than 99%.
2. The method of claim 1, wherein the solvent comprises an alcohol selected from the group consisting of methanol, ethanol, isopropanol, and butanol.
3. The method of claim 1, wherein the solvent comprises a nitrile selected from the group consisting of acetonitrile and propionitrile.
4. The method of claim 1, wherein the solvent comprises a cyclic ether selected from the group consisting of tetrahydrofuran, furan, and ethylene oxide.
5. The method of claim 1, wherein the solvent comprises at least one of DMSO (dimethyl Sulfoxide), DMF (dimethylformamide), and DMA (dimethylacetamide).
6. The method of claim 1, wherein the resulting 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V has a purity of greater than 99.9%.
7. The method of claim 1, comprising using the pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V for the synthesis of safinamide mesylate of formula I.
8. The method of claim 7, wherein the resulting safinamide mesylate of formula I is crystalline.
9. The method of claim 7, wherein the resulting safinamide mesylate of formula I has a purity of greater than 99% and is prepared by reacting pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V with L-alaninamide hydrochloride in the presence of methanol and sodium cyanoborohydride to get safinamide and further reacting the safinamide with methane sulfonic acid using ethyl acetate as solvent to obtain safinamide mesylate.
10. The method of claim 9, wherein the resulting safinamide mesylate of formula I has a purity of greater than 99.9%.
11. The method of claim 1, wherein the resulting crude formula IV, before the first treatment with n-heptane, has a purity of greater than 99%.
12. The method of claim 1, wherein the resulting crude formula IV, before the first treatment with n-heptane, has a purity of greater than 99.9%.
13. The method of claim 1, wherein removing the solvent comprises evaporating the solvent under vacuum.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The FIGURE is illustrative of a characteristic X-ray powder diffraction pattern of Safinamide mesylate.
DETAILED DESCRIPTION
(2) Aspects in the preparation of Safinamide Mesylate are quality and production costs of the end product. Owing to regulatory requirements, high quality standards have to be met. Of interest in this context are purity and content of the active compound. Coupled to purity, it is in particular the spectrum of by-products that needs to be monitored. Minor components have to be toxicologically qualified and assessed. Accordingly, such components are listed in specifications and the maximum occurrence in the product is defined. For product safety, the by-product spectrum and the presence of individual contaminants are kept as low as possible to achieve the desire result.
(3) U.S. Pat. No. 6,335,354, which is incorporated herein by reference discusses the process for the synthesis of Safinamide intermediate 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V. The process involves the reaction of 4-hydroxybenzaldehyde with 1-(chloromethyl)-3-fluorobenzene by using potassium carbonate, potassium iodide in ethanol to get 4-((3-fluorobenzyl)oxy)benzaldehyde as yellow oil. Product formed here is carried to the next reaction without any purification. Genotoxic impurity is formed during this step, which may include:
(4) 1. 4-((4-fluorobenzyl)oxy) benzaldehyde,
(5) 2. 4-((2-fluorobenzyl)oxy) benzaldehyde,
(6) 3. 2-((3-fluorobenzyl)oxy) benzaldehyde,
(7) 4. 3-((3-fluorobenzyl)oxy) benzaldehyde, and
(8) 5. 3-(3-fluorobenzyl)-4((3-fluorobenzyl)oxy)benzaldehyde
(9) Thus there is a need for an improved process that ultimately improves the yield with minimum genotoxic impurity.
(10) In a first embodiment, the present invention involves an improved process for the preparation of Safinamide Mesylate intermediate that includes the steps of:
(11) a) condensation reaction of 4-hydroxybenzaldehyde of formula II with 1-(chloromethyl)-3-fluorobenzene of formula III by using potassium carbonate, potassium iodide in isopropyl alcohol to get crude 4-((3-fluorobenzyl)oxy)benzaldehyde of formula IV.
(12) b) crude is then treated with n-heptane to remove all genotoxic impurity to afford pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V.
(13) Highly pure 4-((3-fluorobenzyl)oxy)benzaldehyde of formula V (Safinamide aldehyde) may then be treated with L-Alaninamide hydrochloride of formula VI in presence of sodium cyanoborohydride and methanol to get Safinamide of formula VII.
(14) Safinamide of formula VII may then be treated with methane sulfonic acid in ethyl acetate to get pure Safinamide mesylate of formula I.
(15) Schematic representation for synthesis of Safinamide mesylate is depicted below:
(16) ##STR00003##
(17) Condensation in step a may include: reaction of 4-hydroxybenzaldehyde with 1-(chloromethyl)-3-fluorobenzene by using base, catalyst in suitable solvent to get crude 4-((3-fluorobenzyl)oxy)benzaldehyde.
(18) Suitable base includes but is not limited to sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide etc.
(19) Suitable catalyst includes but is not limited to sodium iodide, potassium iodide
(20) Suitable solvents which can be used in step a for the preparation of compound II includes alcohols, such as methanol, ethanol, isopropanol, butanol and the like; nitriles, such as acetonitrile, propionitrile and the like; cyclic ether, such as tetrahydrofuran, furan, ethylene oxide, solvents like DMSO, DMF, DMA and the like; any mixtures of two or more thereof. Preferably, alcohol solvent is used, more preferably isopropanol.
(21) A suitable temperature for the reaction of step a, may be between about 20° to about 120° C., preferably between about 40° C. to about 100° C., or preferably about 70° C. to about 90° C., or any other suitable temperatures. The reaction may be carried out for any desired time period ranging from about 30 minutes to about 24 hours or longer.
(22) The isolation of crude intermediate may be induced by using conventional techniques known in the art. For example, useful techniques include but are not limited to concentrating, cooling, separation, stirring, shaking, combining with an anti-solvent, adding seed crystals, evaporation, flash evaporation, simple evaporation, rotational drying, or the like.
(23) The crude that is obtained may carry a small proportion of occluded mother liquor containing a higher percentage of impurities and, if desired, the crude may be washed with a solvent to wash out the mother liquor. Evaporation as used herein refers to distilling of solvent almost completely at atmospheric pressure or under reduced pressure. Flash evaporation as used herein refers to distilling of solvent by using a technique includes but is not limited to tray drying, fluidized bed drying. The recovery of intermediate can be done by decantation, centrifugation, gravity filtration, suction filtration, and the like.
(24) The resulting intermediate may be optionally further purified by using conventional technique known in the art. The techniques may include but not limited to treating the crude product into suitable solvent to get slurry. The recovery of pure intermediate can be done by decantation, centrifugation, gravity filtration, suction filtration, and the like. Drying can be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying can be carried out at temperatures of less than about 60° C., less than about 40° C., less than about 30° C., less than about 20° C., or any other suitable temperatures; at atmospheric pressure or under a reduced pressure; as long as the crystalline intermediate is not degraded in its quality. The drying can be carried out for any desired times until the required product quality is achieved. Suitable time for drying can vary from few minutes to several hours for example from about 30 minutes to about 24 or more hours.
(25) Safinamide mesylate obtained by this process is crystalline in nature. XRD for Safinamide mesylate is depicted in the FIGURE.
(26) The Safinamide Mesylate intermediate synthesize by this route have advantageous properties selected from at least one of: chemical purity, stability—such as storage stability, stability to dehydration, stability to polymorphic conversion, flowability, solubility, morphology or crystal habit, low hygroscopicity and low content of residual solvents.
(27) Certain specific aspects and embodiments of the present application will be explained in more detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the present application in any manner.
EXPERIMENTAL SECTION
Preparation of 4-((3-fluorobenzyl)oxy)benzaldehyde
(28) 4-hydroxybenzaldehyde (10 gm) was dissolved in isopropyl alcohol (40 ml) at room temperature. Potassium carbonate (11.32 gm.) and potassium iodide (0.68 gm.) was added into reaction mass. 3-Fluorobenzyl chloride (10.41 mL) was further added into above reaction mass. The reaction mass was then heated to get 75° C. to 85° C. and stirred for about six hours at the same temperature. After completion of reaction, reaction mass was diluted with water and then extracted with ethyl acetate. Organic layer was evaporated under vacuum to get crude intermediate.
(29) Crude product was then treated with heptane to remove genotoxic impurity and get 4-((3-fluorobenzyl)oxy)benzaldehyde. 4-((3-fluorobenzyl)oxy)benzaldehyde was then dissolved dichloromethane and treated with potassium carbonate. Finally crude was treated with heptane to get pure 4-((3-fluorobenzyl)oxy)benzaldehyde (Safinamide aldehyde) with the following characteristics:
(30) Practical Yield: 8.7 gm
(31) Purity by HPLC: 99.92%
Preparation of Safinamide
(32) First, RBF L-Alaninamide hydrochloride (6.493 gm.) was dissolved in methanol (50 ml) at room temperature. The reaction mass was heated to between about 45° C. to about 55° C. Sodium Cyanoborohydride (4.094 gm) was charged into the above reaction mass at about 45° C. to 55° C. Separately, RBF 4-((3-fluorobenzyl)oxy)benzaldehyde (Safinamide aldehyde) (10 gm) was dissolved in methanol (30 ml). This reaction mass was added slowly into first the RBF at about 45° C. to 55° C. The reaction mass was then stirred for 6 hours at about 45° C. to 55° C.
(33) After completion of the reaction, the reaction mass was diluted with water (50 ml) and Dichloromethane (50 ml) into reaction mass at about 20° C. to about 30° C. Potassium carbonate solution [by using potassium carbonate (5 gm) in process water (50 ml)] was charged into the reaction mass at about 20° C. to 30° C. After stirring for about 30 minutes, layers were separated. Organic layer was distilled out under vacuum below about 50° C. Residue were than dissolved in ethyl acetate (35 ml) and refluxed at about 75° C. to 85° C. The reaction mass was cooled to room temperature (RT), filtered, and washed with ethyl acetate (10 ml). Wet material was then dried under vacuum oven to get Safinamide with a Practical Yield: 9.6 gm.
Preparation of Safinamide Mesylate
(34) Safinamide was dissolved in ethyl acetate at room temperature. The Reaction mass was refluxed at about 75° C. to 85° C. Slowly, methane sulfonic acid solution was added into reaction mass at about 75° C. to 85° C. The reaction mixture was then stirred for about 30 minutes at about 75° C. to 85° C. The reaction mixture was then cooled to about 45° C. to 55° C. and filtered. The material was dried under vacuum 60° C. to get Safinamide mesylate with the following characteristics: Practical Yield: 11.4 gm; Purity by HPLC: 99.98%
(35) While the foregoing has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art, from a reading of the disclosure, that various changes in form and detail can be made without departing from the true scope of the invention.